Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Cebrián, Arancha, Gómez del Pulgar, Teresa, Méndez-Vidal, María José, Gonzálvez, María Luisa, Lainez, Nuria, Castellano, Daniel, García-Carbonero, Iciar, Esteban, Emilio, Sáez, Maria Isabel, Villatoro, Rosa, Suárez, Cristina, Carrato, Alfredo, Munárriz-Ferrándiz, Javier, Basterrechea, Laura, García-Alonso, Mirta, González-Larriba, José Luis, Perez-Valderrama, Begoña, Cruz-Jurado, Josefina, González del Alba, Aránzazu, Moreno, Fernando, Reynés, Gaspar, Rodríguez-Remírez, María, Boni, Valentina, Mahillo-Fernández, Ignacio, Martin, Yolanda, Viqueira, Andrea, García-Foncillas, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259767/
https://www.ncbi.nlm.nih.gov/pubmed/28117391
http://dx.doi.org/10.1038/srep41371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259767/
https://www.ncbi.nlm.nih.gov/pubmed/28117391
http://dx.doi.org/10.1038/srep41371

Ejemplares similares